Shield Therapeutics plc (AIM:STX)

Shield Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-17.66	-27.18	-33.29	-49.79	-26.65
Depreciation & Amortization	1.12	0.71	0.37	2.12	2.19
Other Amortization	-	0.71	0.71	0.74	0.8
Asset Writedown & Restructuring Costs	-	-	-	18.11	-
Stock-Based Compensation	0.79	0.86	0.88	0.91	1.34
Other Operating Activities	7.2	3.55	1.25	1.4	0.01
Change in Accounts Receivable	-8.65	-1.14	-7.01	-2.79	-3.9
Change in Inventory	-3.43	-2.46	-1.45	0.22	-0.35
Change in Accounts Payable	16.76	10.47	1.91	7.27	2.69
Change in Other Net Operating Assets	0.5	7.71	-0.48	-0.78	-0.87
Operating Cash Flow	-3.38	-6.77	-37.13	-22.59	-24.73
Capital Expenditures	-0.02	-0.04	-0.24	-0.06	-0.5
Sale (Purchase) of Intangibles	-0.28	-2.39	-2.71	-2.22	-2.29
Other Investing Activities	0.09	0.27	0.52	0.04	0.02
Investing Cash Flow	-0.21	-2.16	-2.43	-2.25	-2.78
Long-Term Debt Issued	1.71	5.7	29.45	9.08	-
Long-Term Debt Repaid	-0.2	-0.21	-5.99	-0.15	-0.1
Net Debt Issued (Repaid)	1.51	5.49	23.45	8.93	-0.1
Issuance of Common Stock	11.95	0.12	26.82	0.11	37.51
Other Financing Activities	-4.84	-4.18	-0.61	-0.5	0.11
Financing Cash Flow	8.63	1.43	49.66	8.53	37.52
Foreign Exchange Rate Adjustments	0.06	0.07	0.45	-1.13	2.41
Miscellaneous Cash Flow Adjustments	-	-	-	4.5	-
Net Cash Flow	5.1	-7.42	10.55	-12.94	12.43
Free Cash Flow	-3.4	-6.81	-37.37	-22.66	-25.23
Free Cash Flow Margin	-6.85%	-21.15%	-285.56%	-411.98%	-1226.73%
Free Cash Flow Per Share	-0.00	-0.01	-0.05	-0.10	-0.12
Cash Interest Paid	4.84	3.95	0.61	0.4	0.06
Cash Income Tax Paid	0.41	0.76	0.72	-0.71	-0.8
Levered Free Cash Flow	6.24	-12.05	-28.96	-12.7	-17.68
Unlevered Free Cash Flow	10.88	-9.63	-28.33	-12.45	-17.68
Change in Working Capital	5.17	14.58	-7.02	3.93	-2.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.